IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-45180-8.html
   My bibliography  Save this article

A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection

Author

Listed:
  • Lorena M. Coria

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Juan Manuel Rodriguez

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires
    Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Agostina Demaria

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Laura A. Bruno

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Mayra Rios Medrano

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Celeste Pueblas Castro

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Eliana F. Castro

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Sabrina A. Del Priore

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Andres C. Hernando Insua

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires
    Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Ingrid G. Kaufmann

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Lucas M. Saposnik

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • William B. Stone

    (College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University)

  • Lineia Prado

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Ulises S. Notaro

    (Universidad Nacional del Litoral-CONICET; Esperanza)

  • Ayelen N. Amweg

    (Universidad Nacional del Litoral-CONICET; Esperanza)

  • Pablo U. Diaz

    (Universidad Nacional del Litoral-CONICET; Esperanza)

  • Martin Avaro

    (Instituto Nacional de Enfermedades Infecciosas - ANLIS “Dr. Carlos G. Malbrán”. Ciudad Autónoma de Buenos Aires)

  • Hugo Ortega

    (Universidad Nacional del Litoral-CONICET; Esperanza)

  • Ana Ceballos

    (Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, INBIRS-CONICET)

  • Valeria Krum

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Francisco M. Zurvarra

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires
    Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Johanna E. Sidabra

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Ignacio Drehe

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Jonathan A. Baqué

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Mariana Li Causi

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Analia V. De Nichilo

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires
    Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Cristian J. Payes

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Teresa Southard

    (College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University)

  • Julio C. Vega

    (Ciudad Autónoma de Buenos Aires)

  • Albert J. Auguste

    (College of Agriculture and Life Sciences, Fralin Life Science Institute, Virginia Polytechnic Institute and State University
    Virginia Polytechnic Institute and State University)

  • Diego E. Álvarez

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Juan M. Flo

    (Unidad de I+D de Biofármacos, Ciudad Autónoma de Buenos Aires)

  • Karina A. Pasquevich

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

  • Juliana Cassataro

    (Universidad Nacional de San Martín (UNSAM) – Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
    Universidad Nacional de San Martín)

Abstract

In the context of continuous emergence of SARS-CoV-2 variants of concern (VOCs), one strategy to prevent the severe outcomes of COVID-19 is developing safe and effective broad-spectrum vaccines. Here, we present preclinical studies of a RBD vaccine derived from the Gamma SARS-CoV-2 variant adjuvanted with Alum. The Gamma-adapted RBD vaccine is more immunogenic than the Ancestral RBD vaccine in terms of inducing broader neutralizing antibodies. The Gamma RBD presents more immunogenic B-cell restricted epitopes and induces a higher proportion of specific-B cells and plasmablasts than the Ancestral RBD version. The Gamma-adapted vaccine induces antigen specific T cell immune responses and confers protection against Ancestral and Omicron BA.5 SARS-CoV-2 challenge in mice. Moreover, the Gamma RBD vaccine induces higher and broader neutralizing antibody activity than homologous booster vaccination in mice previously primed with different SARS-CoV-2 vaccine platforms. Our study indicates that the adjuvanted Gamma RBD vaccine is highly immunogenic and a broad-spectrum vaccine candidate.

Suggested Citation

  • Lorena M. Coria & Juan Manuel Rodriguez & Agostina Demaria & Laura A. Bruno & Mayra Rios Medrano & Celeste Pueblas Castro & Eliana F. Castro & Sabrina A. Del Priore & Andres C. Hernando Insua & Ingrid, 2024. "A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45180-8
    DOI: 10.1038/s41467-024-45180-8
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-45180-8
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-024-45180-8?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Karina A. Pasquevich & Lorena M. Coria & Ana Ceballos & Bianca Mazzitelli & Juan Manuel Rodriguez & Agostina Demaría & Celeste Pueblas Castro & Laura Bruno & Lucas Saposnik & Melina Salvatori & August, 2023. "Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    2. Saranya Sridhar & Roman M. Chicz & William Warren & Jim Tartaglia & Stephen Savarino & Sanjay Gurunathan & Jean-Francois Toussaint, 2022. "The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022," Nature Communications, Nature, vol. 13(1), pages 1-3, December.
    3. Rahul K. Suryawanshi & Irene P. Chen & Tongcui Ma & Abdullah M. Syed & Noah Brazer & Prachi Saldhi & Camille R. Simoneau & Alison Ciling & Mir M. Khalid & Bharath Sreekumar & Pei-Yi Chen & G. Renuka K, 2022. "Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination," Nature, Nature, vol. 607(7918), pages 351-355, July.
    4. Qian Wang & Yicheng Guo & Sho Iketani & Manoj S. Nair & Zhiteng Li & Hiroshi Mohri & Maple Wang & Jian Yu & Anthony D. Bowen & Jennifer Y. Chang & Jayesh G. Shah & Nadia Nguyen & Zhiwei Chen & Kathrin, 2022. "Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5," Nature, Nature, vol. 608(7923), pages 603-608, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Guoli Shi & Tiansheng Li & Kin Kui Lai & Reed F. Johnson & Jonathan W. Yewdell & Alex A. Compton, 2024. "Omicron Spike confers enhanced infectivity and interferon resistance to SARS-CoV-2 in human nasal tissue," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    2. Ahumada, M. & Ledesma-Araujo, A. & Gordillo, L. & Marín, J.F., 2023. "Mutation and SARS-CoV-2 strain competition under vaccination in a modified SIR model," Chaos, Solitons & Fractals, Elsevier, vol. 166(C).
    3. Weizhong Li & Tao Wang & Arunraj M. Rajendrakumar & Gyanada Acharya & Zizhen Miao & Berin P. Varghese & Hailiang Yu & Bibek Dhakal & Tanya LeRoith & Athira Karunakaran & Wenbin Tuo & Xiaoping Zhu, 2023. "An FcRn-targeted mucosal vaccine against SARS-CoV-2 infection and transmission," Nature Communications, Nature, vol. 14(1), pages 1-18, December.
    4. Saya Moriyama & Yuki Anraku & Shunta Taminishi & Yu Adachi & Daisuke Kuroda & Shunsuke Kita & Yusuke Higuchi & Yuhei Kirita & Ryutaro Kotaki & Keisuke Tonouchi & Kohei Yumoto & Tateki Suzuki & Taiyou , 2023. "Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants," Nature Communications, Nature, vol. 14(1), pages 1-17, December.
    5. Vincent Pavot & Catherine Berry & Michael Kishko & Natalie G. Anosova & Lu Li & Tim Tibbitts & Dean Huang & Alice Raillard & Sylviane Gautheron & Cindy Gutzeit & Marguerite Koutsoukos & Roman M. Chicz, 2023. "Beta variant COVID-19 protein booster vaccine elicits durable cross-neutralization against SARS-CoV-2 variants in non-human primates," Nature Communications, Nature, vol. 14(1), pages 1-8, December.
    6. Katherine U. Gaynor & Marina Vaysburd & Maximilian A. J. Harman & Anna Albecka & Phillip Jeffrey & Paul Beswick & Guido Papa & Liuhong Chen & Donna Mallery & Brian McGuinness & Katerine Rietschoten & , 2023. "Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    7. Qihong Yan & Xijie Gao & Banghui Liu & Ruitian Hou & Ping He & Yong Ma & Yudi Zhang & Yanjun Zhang & Zimu Li & Qiuluan Chen & Jingjing Wang & Xiaohan Huang & Huan Liang & Huiran Zheng & Yichen Yao & X, 2024. "Antibodies utilizing VL6-57 light chains target a convergent cryptic epitope on SARS-CoV-2 spike protein and potentially drive the genesis of Omicron variants," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    8. Saranya Sridhar & Roman M. Chicz & William Warren & Jim Tartaglia & Stephen Savarino & Sanjay Gurunathan & Jean-Francois Toussaint, 2022. "The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022," Nature Communications, Nature, vol. 13(1), pages 1-3, December.
    9. Hung Fu Tseng & Bradley K. Ackerson & Katia J. Bruxvoort & Lina S. Sy & Julia E. Tubert & Gina S. Lee & Jennifer H. Ku & Ana Florea & Yi Luo & Sijia Qiu & Soon Kyu Choi & Harpreet S. Takhar & Michael , 2023. "Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5," Nature Communications, Nature, vol. 14(1), pages 1-10, December.
    10. Zheng Quan Toh & Nadia Mazarakis & Jill Nguyen & Rachel A. Higgins & Jeremy Anderson & Lien Anh Ha Do & David P. Burgner & Nigel Curtis & Andrew C. Steer & Kim Mulholland & Nigel W. Crawford & Shidan , 2022. "Comparison of antibody responses to SARS-CoV-2 variants in Australian children," Nature Communications, Nature, vol. 13(1), pages 1-5, December.
    11. Haohuai He & Bing He & Lei Guan & Yu Zhao & Feng Jiang & Guanxing Chen & Qingge Zhu & Calvin Yu-Chian Chen & Ting Li & Jianhua Yao, 2024. "De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model," Nature Communications, Nature, vol. 15(1), pages 1-19, December.
    12. Mark Chernyshev & Mrunal Sakharkar & Ruth I. Connor & Haley L. Dugan & Daniel J. Sheward & C. G. Rappazzo & Aron Stålmarck & Mattias N. E. Forsell & Peter F. Wright & Martin Corcoran & Ben Murrell & L, 2023. "Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    13. Farina Karim & Catherine Riou & Mallory Bernstein & Zesuliwe Jule & Gila Lustig & Strauss Graan & Roanne S. Keeton & Janine-Lee Upton & Yashica Ganga & Khadija Khan & Kajal Reedoy & Matilda Mazibuko &, 2024. "Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation," Nature Communications, Nature, vol. 15(1), pages 1-16, December.
    14. Cai He & Jingyun Yang & Weiqi Hong & Zimin Chen & Dandan Peng & Hong Lei & Aqu Alu & Xuemei He & Zhenfei Bi & Xiaohua Jiang & Guowen Jia & Yun Yang & Yanan Zhou & Wenhai Yu & Cong Tang & Qing Huang & , 2022. "A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant," Nature Communications, Nature, vol. 13(1), pages 1-14, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-45180-8. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.